GLP-2TRZ is a prescription injectable medication. 

• GIP (glucose-dependent insulinotropic polypeptide)

• GLP-1 (glucagon-like peptide-1)

​

Structurally, GLP-2TRZ is a 39-amino-acid synthetic peptide built mostly on the GIP sequence. A fatty-acid chain is attached so it binds to albumin in the blood, which slows its clearance and gives it a half-life of about five days. That allows a single subcutaneous injection once a week. Treatment usually starts at a low dose and is increased gradually over several months, mainly to limit stomach side effects.

​

How it works

Both incretin hormones are released naturally after a meal, and GLP-2TRZ amplifies their signals in several ways:

• Insulin release: It increases insulin release from the pancreas, but only when blood sugar is elevated. Because of this, it causes little hypoglycemia on its own.

• Glucagon: It suppresses glucagon, the hormone that tells the liver to release sugar.

• Gastric emptying: It slows how quickly the stomach empties, so you feel full longer and post-meal glucose spikes are blunted.

• Appetite: It acts on appetite centers in the brain, chiefly the hypothalamus, to reduce hunger and food cravings.

• GIP-specific effects: The GIP component appears to improve insulin sensitivity and how fat tissue stores and handles lipids. It may also partly offset the nausea associated with GLP-1 activity, though the exact contribution of GIP is still being studied.

• ​

Benefits supported by clinical evidence

Blood sugar control (type 2 diabetes): In the SURPASS trial program, GLP-2TRZ lowered HbA1c by roughly 2 percentage points or more at higher doses. In a head-to-head trial (SURPASS-2) it outperformed semaglutide 1 mg on both glucose control and weight loss. Many patients reached near-normal HbA1c levels.

​

Weight loss: This is its most striking effect. In SURMOUNT-1, people without diabetes on the 15 mg dose lost about 20–22% of body weight over 72 weeks, versus about 3% on placebo. A direct comparison against semaglutide 2.4 mg (SURMOUNT-5) showed about 20% weight loss with GLP-2TRZ versus about 14% with semaglutide. Weight loss is generally somewhat smaller in people with diabetes.

​

Obstructive sleep apnea: In the SURMOUNT-OSA trials, it substantially reduced breathing interruptions during sleep in adults with obesity. This led to FDA approval for moderate-to-severe OSA in late 2024.

​

Heart failure: The SUMMIT trial found that in people with obesity and heart failure with preserved ejection fraction (HFpEF), GLP-2TRZ reduced the combined risk of cardiovascular death or worsening heart failure events and improved symptoms and exercise capacity.

Cardiovascular risk factors: It consistently lowers blood pressure, triglycerides, and LDL cholesterol, and reduces markers of inflammation. 

​